{"id":"lisuride","rwe":[{"pmid":"41855890","year":"2026","title":"The wake of addiction: Pharmacological strategies for sleep disturbances in stimulant use disorders, a systematic review.","finding":"","journal":"Drug and alcohol dependence","studyType":"Clinical Study"},{"pmid":"41745708","year":"2026","title":"Consensus Molecules Associated with Parkinson's Disease.","finding":"","journal":"Neurology international","studyType":"Clinical Study"},{"pmid":"41570169","year":"1993","title":"RAB32-Related Parkinson Disease.","finding":"","journal":"","studyType":"Clinical Study"},{"pmid":"41481361","year":"2026","title":"Snapshot IP(1) Detection Following 5-HT(2)A Receptor Stimulation in the Mouse Brain.","finding":"","journal":"ACS chemical neuroscience","studyType":"Clinical Study"},{"pmid":"41077262","year":"2025","title":"Differential effects of psilocybin and lisuride on serotonin and dopamine neuronal activity and behavior.","finding":"","journal":"Progress in neuro-psychopharmacology & biological psychiatry","studyType":"Clinical Study"}],"tags":[{"label":"lisuride","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Alpha-2A adrenergic receptor","category":"target"},{"label":"ADRA2A","category":"gene"},{"label":"ADRA2B","category":"gene"},{"label":"HTR1A","category":"gene"},{"label":"N02CA07","category":"atc"},{"label":"Active","category":"status"},{"label":"Acromegaly","category":"indication"},{"label":"Amenorrhea","category":"indication"},{"label":"Migraine","category":"indication"},{"label":"Anti-Dyskinesia Agents","category":"pharmacology"},{"label":"Antiparkinson Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Dopamine Agents","category":"pharmacology"},{"label":"Dopamine Agonists","category":"pharmacology"},{"label":"Neurotransmitter Agents","category":"pharmacology"},{"label":"Serotonin Agents","category":"pharmacology"},{"label":"Serotonin Receptor Agonists","category":"pharmacology"}],"phase":"phase_3","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"lisurid","offLabel":[],"synonyms":["lisuride hydrogen maleate","lisuride maleate","lisuride","lisurid","lysuride","mesorgydine","methylergol carbamide","methylergol carbamide maleate"],"timeline":[],"approvals":[],"brandName":"Lisurid","ecosystem":[{"indication":"Acromegaly","otherDrugs":[{"name":"bromocriptine","slug":"bromocriptine","company":"Us Pharms Holdings I"},{"name":"lanreotide","slug":"lanreotide","company":"Ipsen Pharma"},{"name":"octreotide","slug":"octreotide","company":"Novartis"},{"name":"pegvisomant","slug":"pegvisomant","company":"Pharmacia And Upjohn"}],"globalPrevalence":1100000},{"indication":"Amenorrhea","otherDrugs":[{"name":"gonadorelin","slug":"gonadorelin","company":""}],"globalPrevalence":null},{"indication":"Migraine","otherDrugs":[{"name":"acetylsalicylic acid","slug":"acetylsalicylic-acid","company":"Endo Pharms"},{"name":"almotriptan","slug":"almotriptan","company":"Janssen Pharms"},{"name":"caffeine","slug":"caffeine","company":"Novartis"},{"name":"dihydroergotamine","slug":"dihydroergotamine","company":"Valeant"}],"globalPrevalence":1000000000}],"mechanism":{"target":"Alpha-2A adrenergic receptor","targets":[{"gene":"ADRA2A","source":"DrugCentral","target":"Alpha-2A adrenergic receptor","protein":"Alpha-2A adrenergic receptor"},{"gene":"ADRA2B","source":"DrugCentral","target":"Alpha-2B adrenergic receptor","protein":"Alpha-2B adrenergic receptor"},{"gene":"HTR1A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1A","protein":"5-hydroxytryptamine receptor 1A"},{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"},{"gene":"ADRA2C","source":"DrugCentral","target":"Alpha-2C adrenergic receptor","protein":"Alpha-2C adrenergic receptor"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"HTR1D","source":"DrugCentral","target":"5-hydroxytryptamine receptor 1D","protein":"5-hydroxytryptamine receptor 1D"},{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"},{"gene":"DRD5","source":"DrugCentral","target":"D(1B) dopamine receptor","protein":"D(1B) dopamine receptor"},{"gene":"HTR2B","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2B","protein":"5-hydroxytryptamine receptor 2B"}],"modality":"Small Molecule","drugClass":"lisuride","explanation":"Imagine your body has a 'brake' system that helps to slow down certain processes. Lisuride works by pressing this brake, which can help to reduce symptoms of conditions like Migraine and Acromegaly. This is achieved by influencing the release of certain neurotransmitters and hormones.","oneSentence":"Lisuride works by binding to and activating the alpha-2A adrenergic receptor, which helps to regulate various physiological processes.","technicalDetail":"Lisuride acts as a partial agonist at the alpha-2A adrenergic receptor, which is a subtype of adrenergic receptor that plays a role in regulating various physiological processes, including blood pressure, hormone secretion, and neurotransmitter release."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1588","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=LISURIDE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LISURIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:00:03.675452","biosimilars":[],"competitors":[{"drugName":"dihydroergotamine","drugSlug":"dihydroergotamine","fdaApproval":"1946-04-12","patentExpiry":"Sep 5, 2032","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ergotamine","drugSlug":"ergotamine","fdaApproval":"1948-11-26","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"methysergide","drugSlug":"methysergide","fdaApproval":"1962-02-12","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"lisuride","indications":{"approved":[{"name":"Acromegaly","source":"DrugCentral","snomedId":74107003,"regulator":"FDA","usPrevalence":null,"globalPrevalence":1100000,"prevalenceMethod":"curated","prevalenceSource":"Eur J Endocrinol, 2021 (PMID:34061771)"},{"name":"Amenorrhea","source":"DrugCentral","snomedId":14302001,"regulator":"FDA"},{"name":"Migraine","source":"DrugCentral","snomedId":37796009,"regulator":"FDA","usPrevalence":39000000,"globalPrevalence":1000000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet Neurology, 2023"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"dihydroergotamine","brandName":"dihydroergotamine","genericName":"dihydroergotamine","approvalYear":"1946","relationship":"same-class"},{"drugId":"ergotamine","brandName":"ergotamine","genericName":"ergotamine","approvalYear":"1948","relationship":"same-class"},{"drugId":"methysergide","brandName":"methysergide","genericName":"methysergide","approvalYear":"1962","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00089622","phase":"PHASE2","title":"Lisuride Patch to Treat Parkinson's Disease","status":"COMPLETED","sponsor":"National Institute of Neurological Disorders and Stroke (NINDS)","startDate":"2004-08-04","conditions":["Parkinson Disease"],"enrollment":40,"completionDate":"2007-03-31"},{"nctId":"NCT00000338","phase":"PHASE1","title":"Infusion Laboratory: Protocol 2 (Lisuride) - 3","status":"UNKNOWN","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"1996-03","conditions":["Cocaine-Related Disorders"],"enrollment":2,"completionDate":""},{"nctId":"NCT00605683","phase":"PHASE3","title":"MOTION, Safinamide in Early IPD, as add-on to Dopamine Agonist","status":"COMPLETED","sponsor":"Newron Pharmaceuticals SPA","startDate":"2007-11","conditions":["Idiopathic Parkinson's Disease"],"enrollment":679,"completionDate":"2012-03"},{"nctId":"NCT00367822","phase":"PHASE3","title":"Transdermal Lisuride: a Trial for the Treatment of Patients With Restless Legs Syndrome (RLS)","status":"COMPLETED","sponsor":"Axxonis Pharma AG","startDate":"","conditions":["Restless Legs Syndrome"],"enrollment":300,"completionDate":""},{"nctId":"NCT00408915","phase":"PHASE3","title":"Continuous Application of Lisuride in Parkinson's Disease by Subcutaneous Infusion","status":"COMPLETED","sponsor":"Axxonis Pharma AG","startDate":"2006-07","conditions":["Parkinson's Disease"],"enrollment":60,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"003989","UNII":"E0QN3D755O","CHEBI":"CHEBI:51164","INN_ID":"3065","RXNORM":"6446","UMLSCUI":"C0023863","ChEMBL_ID":"CHEMBL157138","KEGG_DRUG":"D01462","DRUGBANK_ID":"DB00589","PDB_CHEM_ID":" H8G","PUBCHEM_CID":"28864","SNOMEDCT_US":"323159002","IUPHAR_LIGAND_ID":"43","SECONDARY_CAS_RN":"19875-60-6","MESH_DESCRIPTOR_UI":"D008090"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","halfLife":"1.8 hours","clearance":"13.3 mL/min/kg","bioavailability":"14%","volumeOfDistribution":"1.73 L/kg"},"publicationCount":762,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N02CA07","allCodes":["G02CB02","N02CA07"]},"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 13","pmid":"41855890","title":"The wake of addiction: Pharmacological strategies for sleep disturbances in stimulant use disorders, a systematic review.","journal":"Drug and alcohol dependence"},{"date":"2026 Jan 27","pmid":"41745708","title":"Consensus Molecules Associated with Parkinson's Disease.","journal":"Neurology international"},{"date":"1993","pmid":"41570169","title":"RAB32-Related Parkinson Disease.","journal":""},{"date":"2026 Jan 21","pmid":"41481361","title":"Snapshot IP(1) Detection Following 5-HT(2)A Receptor Stimulation in the Mouse Brain.","journal":"ACS chemical neuroscience"},{"date":"2025 Oct 2","pmid":"41077262","title":"Differential effects of psilocybin and lisuride on serotonin and dopamine neuronal activity and behavior.","journal":"Progress in neuro-psychopharmacology & biological psychiatry"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lisuride is a small molecule used in the treatment of various conditions, including Parkinson's Disease and Restless Legs Syndrome, through different administration methods such as intravenous and transdermal systems. It has been studied in clinical trials for its potential therapeutic effects on these conditions.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"EU","regulator":"EMA","status":"withdrawn","approval_date":"2009-12-31T00:00:00.000Z","mah":"Axxonis Pharma AG","brand_name_local":"Nenad","application_number":"EMEA/H/C/001020"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}